Pre-made Gedivumab benchmark antibody ( Whole mAb, anti-Influenza A HA therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-238

Pre-Made Gedivumab biosimilar, Whole Mab: Anti-Influenza A HA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

39.29 (gedivumab) is fully human neutralizing monoclonal antibody against influenza A. 39.29 is a neutralizing monoclonal antibody that recognizes the hemagglutinin (HA) glycoprotein of all 16 subtypes and neutralized both group 1 and group 2 influenza A viruses.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-238-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Gedivumab biosimilar, Whole Mab: Anti-Influenza A HA therapeutic antibody
INN Name Gedivumab
TargetInfluenza A HA
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI Structure4kvn:HL
Year Proposed2016
Year Recommended2017
CompaniesGenentech
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedInfluenza A virus infections
Development Techna